At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety of topics, including novel targets, T-cell engager therapy, myeloma at the single-cell level, the role of measurable residual disease (MRD), and more. Leading experts came together to discuss, debate, and answer questions, bringing you the latest in the field.
In this exclusive podcast, Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, and Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York, NY, share some key highlights from day one at this year’s meeting. The experts talk on updates in MRD and prognosis, antibody therapy for amyloidosis, and more.
The post Myeloma 2022: day one highlights appeared first on VJHemOnc.
